Date Posted: August 8, 2026

This Billing and Coding Article has been revised under contract numbers: 01111 (CA), 01211 (AS, GU, HI, NMI), 01311 (NV), and 01911 (CA, HI & Territories).

Effective Date: April 6, 2026

Summary of Changes:

Under Article Text subheading Additional Test-specific Indications, Limitations and Instructions revised 1st sentence to read "neoadjuvant breast cancers (Signatera and NeXT Personal)". Formatting was corrected throughout the article. This revision is due to a new covered test that has successfully completed a TA and is effective for 04/06/2026.

Visit the Noridian Molecular Diagnostic Services webpage to view the Active MolDX LCDs or access it via the CMS MCD.